Last Updated on July 9, 2026 4:23 pm by BIZNAMA NEWS
NEWS DESK
Dr Reddy’s shares tumbled 7% as quality issue delays commercial launch of semaglutide- Dr Reddy’s Laboratories said on Thursday that it is delaying commercial supplies of semaglutide due to an issue related to the active pharmaceutical ingredient used in the drug, sending its shares down.
Semaglutide is the key ingredient in Novo Nordisk’s blockbuster diabetes and obesity medicines. Dr Reddy’s has also launched its semaglutide injection, Obeda, in India to treat diabetes.
The Indian drugmaker said that certain batches of semaglutide were found to be out of specification and that it is investigating the root cause and taking measures to ensure product quality.
“There is no impact on patient safety or on the product’s existing global regulatory filings,” Dr Reddy’s said in a statement.
Dr Reddy’s did not specify until when the supply issues would last and did not disclose further details.